



REGULATED INFORMATION • REGULATED INFORMATION • REGULATED INFORMATION

HALF YEAR REPORT ON THE LIQUIDITY CONTRACT

Under the liquidity contract entered into between NEOVACS and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30th 2019:

- 892,417 shares
- € 104,364.00

For the prior (December 31, 2017), the corresponding figures were:

- 894,000 shares
- € 71,044.44

About Neovacs

Listed on Euronext Growth since 2010, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by four patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFN α Kinoid, an immunotherapy being developed for the indication of lupus and dermatomyositis. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology, allergies and Type 1 diabetes. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. www.neovacs.fr